Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. JW (Cayman) Therapeutics Co. Ltd
  6. News
  7. Summary
    2126   KYG5210T1040

JW (CAYMAN) THERAPEUTICS CO. LTD

(2126)
  Report
End-of-day quote. End-of-day quote Hong Kong Stock Exchange - 01/21
11.28 HKD   +0.71%
01/10JW Therapeutics Appoints Immunotherapy Expert as Chief Scientific Officer
MT
01/09JW Therapeutics Announces Management Appointments
CI
2021JW Therapeutics Grants Share Options to Certain Employees
MT
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

JW Therapeutics Co. Ltd Announces NMPA Approval of Relmacabtagene Autoleucel Injection in China

09/03/2021 | 12:29am EST

The board (the "Board") of directors (the "Directors") of JW (Cayman) Therapeutics Co. Ltd. announced that, the National Medical Products Administration (the "NMPA") of China has approved the New Drug Application ("NDA") for the Company's anti-CD19 autologous chimeric antigen receptor T ("CAR-T") cell immunotherapy product relmacabtagene autoleucel injection ("relma-cel"), R&D code: JWCAR029) for the treatment of adult patients with relapsed or refractory large B-cell lymphoma ("r/r LBCL") after two or more lines of systemic therapy. Relma-cel is the first CAR-T product approved as a Category 1 biologics product in China, and sixth approved CAR-T product globally. Relma-cel, JW Therapeutics' first CAR-T product, was independently developed based on a CAR-T cell process platform of Juno Therapeutics (a Bristol Myers Squibb company) to meet the needs of the Chinese market. Currently, it is the only approved CAR-T product in China that has been simultaneously included in the National Significant New Drug Development Program, granted priority review (for relma-cel as a treatment of r/r LBCL) and breakthrough therapy designations (for relma-cel as a treatment of follicular lymphoma). To date, over 100 patients have been dosed with relma-cel in clinical studies, making relma-cel the most studied anti-CD19 CAR-T product in China. This approval is based on the results of a single-arm, multi-center, pivotal study ("RELIANCE study") to evaluate the efficacy and safety of relma-cel in patients with r/r LBCL in China. RELIANCE study results show that relma-cel demonstrated high rates of durable disease response and low rates of CAR-T associated toxicities, and may provide a best-in-class CAR-T therapy profile.


© S&P Capital IQ 2021
All news about JW (CAYMAN) THERAPEUTICS CO. LTD
01/10JW Therapeutics Appoints Immunotherapy Expert as Chief Scientific Officer
MT
01/09JW Therapeutics Announces Management Appointments
CI
2021JW Therapeutics Grants Share Options to Certain Employees
MT
2021JW Therapeutics Co. Ltd Announces Executive Changes
CI
2021JW Therapeutics Presents Immunotherapy Study Findings at US Conference; Shares Jump 4%
MT
2021JW Therapeutics Co. Ltd Announces Board and Committee Changes
CI
2021JW CAYMAN THERAPEUTICS : Therapeutics Awards 7 Million Share Options, Nearly 5 Million Res..
MT
2021JW (CAYMAN) THERAPEUTICS : to Start Clinical Trials of Multiple Myeloma Treatment in China
MT
2021JW Therapeutics Announces IND Approval for the Clinical Trial of JWCAR129
CI
2021JW CAYMAN THERAPEUTICS : Therapeutics Says Immunotherapy Shows Long-Term Efficacy in Large..
MT
More news
Financials
Sales 2021 64,6 M 10,2 M 10,2 M
Net income 2021 -628 M -99,1 M -99,1 M
Net cash 2021 1 836 M 290 M 290 M
P/E ratio 2021 -6,42x
Yield 2021 -
Capitalization 3 743 M 591 M 591 M
EV / Sales 2021 29,5x
EV / Sales 2022 7,85x
Nbr of Employees 477
Free-Float 56,2%
Chart JW (CAYMAN) THERAPEUTICS CO. LTD
Duration : Period :
JW (Cayman) Therapeutics Co. Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JW (CAYMAN) THERAPEUTICS CO. LTD
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 9,18 CNY
Average target price 20,67 CNY
Spread / Average Target 125%
EPS Revisions
Managers and Directors
Yi Ping Li Chairman & Chief Executive Officer
Xin Fu Chief Financial Officer & Senior Vice President
Lapyuen Harry Lam Chief Technology Officer & Executive VP
Shaun Paul Cordoba Chief Scientific Officer
Chi Shing Li Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
JW (CAYMAN) THERAPEUTICS CO. LTD-16.07%591
GILEAD SCIENCES, INC.-5.65%85 938
REGENERON PHARMACEUTICALS-2.71%64 971
VERTEX PHARMACEUTICALS3.86%57 990
WUXI APPTEC CO., LTD.-9.18%49 645
BIONTECH SE-42.79%35 624